In addition, 69% (20/29) and 40% (13/29) of patients were detected with PD-L1 positive expression (PD-L1 ≥ 1%), and high PD-L1 expression (PD-L1 ≥ 50%) in these 29 NSCLC patients harbored BRAF mutation [16]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.